Best GLP-1 for Weight Loss: How the Top Options Compare

If you are looking for the single best GLP-1 for weight loss on average magnitude alone, the current answer is tirzepatide (sold as Zepbound for weight management), which produced about 21% mean weight loss in its pivotal trial and beat semaglutide head-to-head. But "best on average" and "best for you" are not the same question. The most effective GLP-1 for weight loss in any individual case depends on how well you tolerate it, how it is dosed, what it costs through your access route, and what a clinician judges fits your health history. This guide compares the leading options honestly, including where each one wins.

There is no single best GLP-1 for weight loss that suits everyone, and any page that names one without caveats is overselling. Below is what the trials actually show, a side-by-side comparison table, and a plain account of who each option tends to suit.

The short answer: which GLP-1 produces the most weight loss

Ranked by average weight loss in clinical trials, the order is consistent. A 2024 systematic review of 53 studies placed tirzepatide first, then semaglutide, then liraglutide, then the older agents (dulaglutide, exenatide). The two that matter for most people shopping for weight loss are the top two.

• Tirzepatide (Zepbound for weight, Mounjaro for diabetes): up to about 20.9% mean weight loss over 72 weeks on the 15mg dose in SURMOUNT-1.
• Semaglutide (Wegovy for weight, Ozempic for diabetes): about 14.9% mean weight loss over 68 weeks on the 2.4mg dose in STEP 1.

The clearest evidence is the SURMOUNT-5 head-to-head trial, which compared the two directly. At 72 weeks, tirzepatide produced roughly 20.2% mean weight loss versus 13.7% for semaglutide, and a far higher share of tirzepatide patients reached at least 15% loss. On raw efficacy, tirzepatide is the most effective GLP-1 for weight loss currently available. That is the honest headline. The rest of this guide is why it is not the whole story.

Why the best GLP-1 for weight loss depends on the person

Averages hide wide individual variation. In every one of these trials, some people lost a great deal and a minority lost very little, and the trials do not predict in advance who will fall where. A drug that is second on the average chart can still be the best GLP-1 for weight loss for a specific person, for several concrete reasons.

Tolerance. Both drugs share the same gastrointestinal side-effect profile (nausea, constipation, diarrhoea), and both settle for most people as the dose is titrated up slowly. But individuals differ. Someone who feels persistently unwell on one molecule may do fine on the other, and the more effective drug on paper is useless if you cannot stay on it.

Mechanism. Semaglutide activates the GLP-1 receptor alone. Tirzepatide is a dual agonist that activates both GLP-1 and GIP receptors, which is the leading explanation for its larger average effect. The deeper biology sits in our explainers on how semaglutide works for weight loss and how tirzepatide works, and the class as a whole in the GLP-1 receptor agonist drug class.

Dosing and route. Both are once-weekly injections that step up over months. Semaglutide also exists as a daily oral tablet (Rybelsus), which matters for people who will not inject. An injection-versus-tablet preference can decide which option a person actually sticks with.

Cost and access. List prices for both sit above $1,000 a month, and what you pay depends entirely on insurance, manufacturer self-pay programmes, and which brand your plan covers. The cheapest available option for you can outrank the most effective one on the chart. We break the routes down in the cost section below.

Indication and history. For weight management specifically, the FDA-approved options are Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). Your medical history, including any contraindications, is a clinician's call. See who qualifies for a GLP-1 prescription.

Comparison table: the best GLP-1 options for weight loss

This table compares the leading GLP-1 medications for weight loss on the factors that actually drive the decision. Figures are mean trial results; individual outcomes vary widely.

Medication (weight brand)	Active ingredient	Mechanism	Avg. weight loss (trial)	Dosing	Best suited to
Zepbound	Tirzepatide	GLP-1 + GIP dual agonist	~20.9% over 72 wks (SURMOUNT-1)	Weekly injection	Those prioritising maximum average weight loss who tolerate it
Wegovy	Semaglutide	GLP-1 agonist	~14.9% over 68 wks (STEP 1)	Weekly injection	Strong all-rounder with the longest track record and cardiovascular data
Saxenda	Liraglutide	GLP-1 agonist (short-acting)	~8% over 56 wks	Daily injection	People who need a shorter-acting option or for whom newer agents are unsuitable
Rybelsus (off-label for weight)	Semaglutide (oral)	GLP-1 agonist	Lower than injectable doses	Daily tablet	People who will not inject; smaller effect at current doses

Two brands worth untangling: Ozempic and Wegovy are the same molecule (semaglutide) at different doses and labels, as are Mounjaro and Zepbound (tirzepatide). The distinctions matter for cost and coverage, which is why we cover them in Ozempic vs Wegovy and Mounjaro vs Zepbound. For the direct drug-versus-drug breakdown, see semaglutide vs tirzepatide.

Tirzepatide vs semaglutide: the head-to-head detail

Because these two dominate the "best GLP-1 for weight loss" question, they deserve a closer look. In the SURMOUNT-1 trial, the highest tirzepatide dose produced about 20.9% mean weight loss, and more than half of patients on the top dose lost over 20% of their starting weight, figures that overlap at the high end with bariatric surgery. In STEP 1, semaglutide produced about 14.9% mean loss, with roughly 86% of patients losing at least 5%.

The head-to-head SURMOUNT-5 trial removed the cross-study guesswork by testing both in the same population, and tirzepatide came out ahead on every weight metric. Tolerability was broadly similar, with some signals that tirzepatide may be marginally better tolerated. None of this makes semaglutide a weak choice. It has the longest real-world track record, and a large cardiovascular outcomes trial (SELECT) showed semaglutide reduces the risk of major adverse cardiovascular events in people with overweight or obesity and established heart disease, the first weight-management GLP-1 to demonstrate that benefit. For someone whose priority is cardiovascular risk as much as the number on the scale, that evidence carries weight. What semaglutide does week to week in practice is covered in weight loss on semaglutide.

Side effects: similar across the class

The side-effect profile is broadly the same across GLP-1 medications because it follows directly from the shared mechanism. The dominant effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and early fullness. In both STEP 1 and SURMOUNT-1 these were mostly mild to moderate and led only a small minority to stop treatment.

The reason is slowed gastric emptying, which is part of how the satiety effect works but can tip into nausea, especially after large or fatty meals and early in treatment. This is why every option in this class is titrated: started low and increased in steps over weeks to months so the gut adapts. Rushing the titration is one of the most common reasons people get side effects bad enough to quit. Smaller, slower meals, less fatty food, and adequate hydration all help. Rarer serious risks (pancreatitis, gallbladder disease, and a contraindication in people with a personal or family history of medullary thyroid carcinoma) are part of why these are prescription drugs evaluated by a clinician, not casual purchases.

Cost: often the real deciding factor

For many people the best GLP-1 for weight loss is, in practice, the one they can afford on a sustained basis, because these are long-term treatments rather than a short course. List prices for both leading drugs sit above $1,000 a month, but almost nobody uninsured pays that. The real cost depends on your route:

• Insurance: a copay if your plan covers the drug for your indication, though many plans exclude weight-management use and require prior authorization.
• Manufacturer self-pay: Lilly's LillyDirect (Zepbound) and Novo Nordisk's NovoCare (Wegovy) offer predictable cash pricing well below list, with Zepbound vials among the lower-cost branded routes.
• Savings cards: sharp reductions for the commercially insured whose plan excludes the drug; these exclude Medicare and Medicaid.

Because pricing and coverage shift often, the cheapest route for your specific drug and dose is worth re-checking rather than assuming. Cost can legitimately move the "best for me" answer from tirzepatide to semaglutide or the reverse, depending on what your plan covers.

How to actually get started

Deciding which GLP-1 is best for your weight loss is a clinical conversation, not a self-diagnosis. A prescriber weighs your BMI, weight-related conditions, medical history, tolerance, and budget against the options above, then chooses a starting drug and titration plan. Eligibility generally starts at a BMI of 30, or 27 with a weight-related condition, though specifics vary by drug and country; the detail is in who qualifies for a GLP-1 prescription.

Access has become considerably easier through legitimate online telehealth providers, which can evaluate you, prescribe an appropriate GLP-1 if suitable, and route it through a manufacturer or licensed pharmacy with follow-up built in. For many people this is the most practical path to starting treatment with proper medical oversight, especially where local in-person obesity-medicine appointments are scarce or slow. The important filter is legitimacy: a real clinician who evaluates you and is reachable for follow-up, a credentialed pharmacy, and transparent sourcing, rather than a checkout page that ships after a one-line form. For the full mechanism, trial, and safety context behind every option here, see our complete guide to GLP-1 medications and weight science.

Key takeaways

• On average magnitude, tirzepatide (Zepbound) is the most effective GLP-1 for weight loss, beating semaglutide head-to-head (about 20% vs 14% in SURMOUNT-5).
• There is no single best GLP-1 for weight loss for everyone; tolerance, dosing, cost, and medical history can make a "second-place" drug the right one for you.
• Semaglutide has the longest track record and proven cardiovascular benefit (SELECT), making it a strong all-round choice.
• Side effects are similar across the class, mostly transient gastrointestinal symptoms managed by slow titration.
• Cost and insurance coverage often decide the practical answer; compare your insurance, manufacturer self-pay, and savings-card options for your specific drug.
• The choice belongs with a clinician; legitimate telehealth providers make starting treatment with proper oversight more accessible.

Want clear, unbiased GLP-1 guidance without the sales pitch? Modern Weight Science is independent and evidence-based. Subscribe to our free weekly newsletter for plain-English updates on what works, what it costs, and the science behind it.